HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides

Author(s): J. Lin, S. Denmeade, M. A. Carducci

Journal Name: Current Cancer Drug Targets

Volume 9 , Issue 7 , 2009

Become EABM
Become Reviewer
Call for Editor


Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na+K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.

Keywords: HIF-1α, Calcium, Prostate cancer, digoxin, cardiac glycosides

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [881 - 887]
Pages: 7
DOI: 10.2174/156800909789760249
Price: $65

Article Metrics

PDF: 14